Diphenyl phthalate (DPHP) is an organic compound with the formula C20H14O4. It is a white solid that is used as a plasticizer, a substance that makes polymers more flexible. DPHP is also used in some types of paints and varnishes. It is produced by the reaction of phthalic anhydride with phenol. DPHP is not a common compound, and its synthesis is not widely studied. However, its effects have been studied in various contexts. For instance, it has been found to have endocrine-disrupting effects, interfering with the hormone system of animals. It is also considered a potential environmental contaminant, as it can accumulate in the environment and persist for long periods. Further research on DPHP is crucial to understand its environmental impact and potential health risks.'
diphenyl phthalate : The diphenyl ester of benzene-1,2-dicarboxylic acid.
ID Source | ID |
---|---|
PubMed CID | 6778 |
CHEMBL ID | 1704716 |
CHEBI ID | 60819 |
SCHEMBL ID | 69868 |
Synonym |
---|
smr001253898 |
1,2-benzenedicarboxylic acid, 1,2-diphenyl ester |
CHEBI:60819 , |
AKOS015840690 |
nsc-4052 |
phthalic acid, diphenyl ester |
84-62-8 |
phenyl phthalate |
nsc4052 |
diphenyl phthalate |
mls002637723 , |
1,2-benzenedicarboxylic acid, diphenyl ester |
diphenyl benzene-1,2-dicarboxylate |
inchi=1/c20h14o4/c21-19(23-15-9-3-1-4-10-15)17-13-7-8-14-18(17)20(22)24-16-11-5-2-6-12-16/h1-14 |
ai3-00131 |
epa pesticide chemical code 017001 |
einecs 201-546-4 |
brn 2473390 |
caswell no. 399b |
nsc 4052 |
diphenyl phthalate, 99% |
phthalic acid diphenyl ester |
P0305 |
A7041 |
NCGC00246808-01 |
NCGC00246808-02 |
cas-84-62-8 |
dtxsid3021778 , |
NCGC00254839-01 |
tox21_300937 |
dtxcid801778 |
unii-bu20109xhv |
bu20109xhv , |
4-09-00-03217 (beilstein handbook reference) |
FT-0625236 |
diphenyl phthalate [mi] |
1,2-benzenedicarboxylic acid 1,2-diphenyl ester |
diphenylphthalate |
SCHEMBL69868 |
1,2-diphenyl benzene-1,2-dicarboxylate |
W-104110 |
DWNAQMUDCDVSLT-UHFFFAOYSA-N |
CHEMBL1704716 |
mfcd00003038 |
diphenyl phthalate, pestanal(r), analytical standard |
phthalic acid, bis-phenyl ester |
diphenyl-phthalate |
Q27128638 |
Z104506004 |
EN300-21625 |
A864047 |
BS-23534 |
CS-0014066 |
Class | Description |
---|---|
phthalate ester | |
diester | A diester is a compound containing two ester groups. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 56.2341 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 10.0000 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 55.9333 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
USP1 protein, partial | Homo sapiens (human) | Potency | 4.4668 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 14.6929 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 47.3174 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743054; AID743063 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 25.1189 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 31.1216 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
progesterone receptor | Homo sapiens (human) | Potency | 24.3365 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 48.5577 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 5.0919 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 56.7014 | 0.0002 | 29.3054 | 16,493.5996 | AID743078; AID743080; AID743091 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 19.4938 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 19.4938 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 76.9588 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 11.3043 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 19.4938 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 56.2341 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 50.1187 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 64.8601 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 70.7946 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 61.1306 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 3.1623 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.69) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |